Autor: |
Cerys, Jenkins, Freya, Woods, Susan, Chandler, Kym, Carter, Rhys, Jenkins, Andrew, Cunningham, Kayleigh, Nelson, Rachel, Still, Jenna A, Walters, Non, Gwynn, Wilson, Chea, Rachel, Harford, Claire, O'Neill, Julie, Hepburn, Ian, Hill, Heather, Wilkes, Greg, Fegan, Peter, Dunstan, Dean A, Harris |
Rok vydání: |
2022 |
Zdroj: |
BJGP open. |
ISSN: |
2398-3795 |
Popis: |
The majority of colorectal cancers (CRCs) are detected after symptomatic presentation to primary care. Given the shared symptoms of CRC and benign disorders it is challenging to manage this risk of missed diagnosis. Colonoscopy resources cannot keep pace with increasing demand. There is a pressing need for access to simple triage tools in primary care to help prioritise patients for referral.To evaluate the performance of a novel spectroscopy-based CRC blood test in primary care.Mixed methods pilot study of test performance and GP focus group discussions.Urgent suspected cancer patients were recruited for the Raman spectroscopy (RS) test coupled to machine learning classification ('Raman-CRC') to identify CRC within the referred population. Qualitative focus group work evaluated the acceptability of the test in primary care by thematic analysis of focus group theorising.532 patients age over 50 referred on the USC pathway were recruited from 27 GP practices. Twenty nine patients (5%) were diagnosed with CRC. Raman-CRC identified CRC with sensitivity 95.7%, specificity 69.3% with Area Under Curve (AUC) of 0.80 as compared to colonoscopy as reference test (248 patients). Stage I/II cancers were detected with 78.6% sensitivity. Focus group themes underlined the convenience of a blood test for the patient and the test's value as a risk assessment tool in primary care.Our findings support this novel, non-invasive blood-based method to prioritise those patients most likely to have CRC. Raman-CRC may accelerate access to diagnosis with potential to improve cancer outcomes. |
Databáze: |
OpenAIRE |
Externí odkaz: |
|